Pharmacopeia Inc

Pharmacopeia — Pharmacopeia Drug Discovery — Investor Presentation (January 2005)

22 slides from Pharmacopeia's investor presentation, Jan 10, 2005

  1. Slide 1: New Opportunity

    Slide 1: New Opportunity

    PHARMACOPEIA DRUG DISCOVERY New Opportunity Pharmacopeia Drug Discovery, Inc. is a biopharmaceutical company, focused on the creation of new small molecule therapeutics for significant unmet medical needs 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  2. Slide 2: Strategic Value Capture Points

    Slide 2: Strategic Value Capture Points

    Strategic Value Capture Points Hi Market Value products Lo Lo Investment (Time, $, IP) 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  3. Slide 3: Intellectual Capital and Experience

    Slide 3: Intellectual Capital and Experience

    Over 160/patents filed with 69 issued + Chemistry - 92 + Biology = 29 + Engineering - 36 ° Software -5 160 Employees (140 scientists) + Chemistry - 80 + Biology - 40 + Engineering & Informatics - 20 + General & Administrative - 20 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  4. Slide 4: Drug Discovery Capabilities

    Slide 4: Drug Discovery Capabilities

    Drug Discovery Capabilities Assay Development Medicinal Chemistr omputational ia brug bi Pharmacopeia Drug Discovery ‘Compound. and Development Collection Pharmacology 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  5. Slide 5: Recent Collaboration Milestones

    Slide 5: Recent Collaboration Milestones

    9/27/04 Pharmacopeia Delivers Leads and Triggers Research Milestone in Collaboration with Neurocrine 10/5/04 Pharmacopeia Achieves Preclinical Development Candidate Milestone in Collaboration with Schering-Plough 10/26/04 Biovitrum AB and Pharmacopeia Form Strategic Research Alliance 4U3009510 9NuG

  6. Slide 6: Strategy

    Slide 6: Strategy

    Strategy Generate maximum return on the existing asset base in the near-term, whilst offering greater future returns on investments being made at Pharmacopeia today © Advance and expand the portfolio of wholly-owned therapeutic product programs ° Evolve the successful collaborative drug discovery bu

  7. Slide 7: Raise Pharmacopeia profile

    Slide 7: Raise Pharmacopeia profile

    Raise Pharmacopeia profile Maintain existing business Build the internal portfolio Sow seeds for future growth Focus Communicate the opportunity Evolve the collaboration model Retain to clinical Phase II Build in immunobiology 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  8. Slide 8: Rheumatoid Arthritis / Psoriasis

    Slide 8: Rheumatoid Arthritis / Psoriasis

    Rheumatoid Arthritis / Disease ne drug modulates underlying mul Psoriasis le process eases 4U3009510 9NuG gage bisdO2BWEOHd Gee

  9. Slide 9: Business Evolution

    Slide 9: Business Evolution

    PHARMACOPEIA DRUG DISCOVERY January 2005 Business Evolution

  10. Slide 10: Robust Pipeline

    Slide 10: Robust Pipeline

    Robust Pipeline In Vitro Lead Optimization ©) In Clinical Trials w/ Collaborators 4 Lead Discovery 20+ 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  11. Slide 11: Research & Development Product Portfolio

    Slide 11: Research & Development Product Portfolio

    Research & Development Product Portfolio Pssieaos Psaoanes Peta pszatez2 Pseoange Pseott6a porrenaa pssrares Internal Programs Pseneso4 pscoenze Poezeaor Fredinioal nies Phase Lead Program | Partner Gansctton OFfimization Development | 1 i Bheunatid — orto ye A | amiss su ‘Asthmallleigy Daiichi Vad

  12. Slide 12: p38 MAP Kinase Inhibition

    Slide 12: p38 MAP Kinase Inhibition

    p38 MAP Kinase Inhibition * P38 is a member of the MAP kinase superfamily * Independent activation pathway responsive to stress stimuli: — inflammatory cytokines, endotoxin, osmotic, UV, chemical stress * Regulates production of inflammatory cytokines — TNF-«, IL-1, IL-6, IL-8 4U3009510 9NuG gage bi

  13. Slide 13: P38 kinase: Central Role in Inflammation

    Slide 13: P38 kinase: Central Role in Inflammation

    P38 kinase: Central Role in Inflammation RA — anti-TNFo Enbrel RA - anti IL-1 Remicade Humira Kineret Blocks the inflammatory effects of TNF & IL-1 PS 516895 in clinical Phase | 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  14. Slide 14: Mechanism of Action

    Slide 14: Mechanism of Action

    Mechanism of Action Reversible in| r unlike BIRB-796 CNS Safety No CNS penetration compared to VX-745 Liver Safety Superior CYP profile to Phil candidates Specificity for p38 il ity for diminished off-target effects Efficacy Efficacious at very low doses 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aie

  15. Slide 15: Molecular Basis of Angiogenesis

    Slide 15: Molecular Basis of Angiogenesis

    Molecular Basis of Angiogenesis A @ Angiogenic @ EC receptor binding “~~ factorproduction Pi icasc... intracellular signaling @ EC activation BM degradation EC proliferation © Directional ~ migration Femcoth muscle cal @ ECM remodeling ® Tube formation ® Loop formation ® Vascular stabilization Angio

  16. Slide 16: Physiology and Pathology of avB3

    Slide 16: Physiology and Pathology of avB3

    1. 2. Physiology and Pathology of avB3 Role in Angiogenesis avp3 is expressed on i. retinal vasculature of patients with Age-related Macular Degeneration (AMD) ii. vascular endothelial cells from patients with Proliferative Diabetic Retinopathy (PDR) avp3 expression is linked to neoplastic progressi

  17. Slide 17: Pharmacopeia Drug Discovery

    Slide 17: Pharmacopeia Drug Discovery

    ray PHARMACOPEIA DRUG DISCOVERY January 2005 qui ‘UoNeZUeINISeACeN jo ealy

  18. Slide 18: PS388023 inhibits retinal neovascularization

    Slide 18: PS388023 inhibits retinal neovascularization

    PS388023 inhibits retinal neovascularization Vehicle cRGD PS$388023 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  19. Slide 19: The Next Months

    Slide 19: The Next Months

    The Next 12 months Continuing milestone flow from collaborations Expanded product portfolio Partnered programs should advance Addition of key pre-clinical and clinical assets Internal programs towards preclinical development 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  20. Slide 20: ly product |

    Slide 20: ly product |

    ly product | eston + Intelle

  21. Slide 21: Financial Summary

    Slide 21: Financial Summary

    Financial Summary $24-28MM in revenues for 2004 $40MM in cash 12.3 million shares 52 week range $4.46 - $10.35 (currently $5-6) Market Cap = ~ $70MM Enterprise value = ~ $30MM 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

  22. Slide 22: Searchable

    Slide 22: Searchable

    Searchable text section of graphics shown above January 2005 [ LOG O] New Opportunity Pharmacopeia Drug Discovery, Inc. is a biopharmaceutical company, focused on the creation of new small molecule therapeutics for significant unmet medical needs Str ategic Value Capture Points [CHART] [ GRA PHIC] I

Source: SEC EDGAR · 8-K filed Jan 10, 2005

More decks from Pharmacopeia Inc